CN110368487A - 一种改善心脑血管健康状况的功能性营养食品 - Google Patents
一种改善心脑血管健康状况的功能性营养食品 Download PDFInfo
- Publication number
- CN110368487A CN110368487A CN201910733483.9A CN201910733483A CN110368487A CN 110368487 A CN110368487 A CN 110368487A CN 201910733483 A CN201910733483 A CN 201910733483A CN 110368487 A CN110368487 A CN 110368487A
- Authority
- CN
- China
- Prior art keywords
- parts
- cardiovascular
- nutrient food
- functional nutrient
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 30
- 235000013305 food Nutrition 0.000 title claims abstract description 19
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 18
- 230000003862 health status Effects 0.000 title claims description 5
- 239000002994 raw material Substances 0.000 claims abstract description 11
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims abstract description 10
- 239000000843 powder Substances 0.000 claims abstract description 10
- 244000068988 Glycine max Species 0.000 claims abstract description 8
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 8
- 239000000284 extract Substances 0.000 claims abstract description 8
- 102000007625 Hirudins Human genes 0.000 claims abstract description 6
- 108010007267 Hirudins Proteins 0.000 claims abstract description 6
- 241000237636 Pheretima Species 0.000 claims abstract description 6
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims abstract description 6
- 229940006607 hirudin Drugs 0.000 claims abstract description 6
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 5
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 5
- 229920001353 Dextrin Polymers 0.000 claims abstract description 5
- 239000004375 Dextrin Substances 0.000 claims abstract description 5
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 5
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 5
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 5
- 102000003797 Neuropeptides Human genes 0.000 claims abstract description 5
- 108090000189 Neuropeptides Proteins 0.000 claims abstract description 5
- 235000019425 dextrin Nutrition 0.000 claims abstract description 5
- 229960000304 folic acid Drugs 0.000 claims abstract description 5
- 235000019152 folic acid Nutrition 0.000 claims abstract description 5
- 239000011724 folic acid Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 229940026314 red yeast rice Drugs 0.000 claims abstract description 5
- 239000002775 capsule Substances 0.000 claims abstract description 4
- 235000013339 cereals Nutrition 0.000 claims abstract description 4
- 229920002472 Starch Polymers 0.000 claims abstract description 3
- 235000013361 beverage Nutrition 0.000 claims abstract description 3
- 229940100688 oral solution Drugs 0.000 claims abstract description 3
- 229920001592 potato starch Polymers 0.000 claims abstract description 3
- 235000019698 starch Nutrition 0.000 claims abstract description 3
- 239000008107 starch Substances 0.000 claims abstract description 3
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 25
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 12
- 230000036541 health Effects 0.000 abstract description 9
- 230000009467 reduction Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000003449 preventive effect Effects 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 208000021479 Cardiovascular injury Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 241001495098 Lumbricus rubellus Species 0.000 description 1
- 102000002568 Multienzyme Complexes Human genes 0.000 description 1
- 108010093369 Multienzyme Complexes Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 241001165494 Rhodiola Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001194 anti-hemostatic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008455 cerebrovascular function Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 108010070324 lumbrokinase Proteins 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Marine Sciences & Fisheries (AREA)
- Food Science & Technology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
本发明提供一种调节心脑血管健康和减少心脑血管疾病风险的功能性营养食品。采用以下技术方案：包含以下重量份的有效活性成分原料：纳豆冻干粉20份，红景天提取物15份，水蛭素5份，地龙3份。叶酸2份，丹参3份，刺五加5份，银杏5份，神经肽2份，红曲5份，藏红花8份。占药材总重量的10％～20％重量份的辅料，所述的辅料可以是谷类淀粉、或薯类淀粉，或糊精。各原料采用常规制法制成片剂、胶囊剂、口服液或饮料。本发明功能性营养食品配方设计合理巧妙，各组分间相互协同，最大极致的发挥对心脑血管疾病的预防和治疗作用，且该产品安全、有效率高、无毒副作用，是一种预防和治疗心脑血管疾病的最佳的功能性营养食品。
Description
技术领域
本发明涉及一种营养食品，具体涉及一种能够改善心脑血管健康状况的功能性营养食品。
背景技术
心脑血管疾病就是心脏血管和脑血管的疾病统称，常见病症有心脏病、中风、老年痴呆症、帕金森综合症、高血脂、高血糖和高血压等。心脑血管疾病是一种严重威胁人类健康的常见病，它具有发病率高、致残率高、死亡率高、复发率高、并发症多的特点。目前，我国心脑血管疾病患者已经超过3亿人，每年死于心脑血管疾病近300万人，占我国每年总死亡病因的51%。心脑血管疾病严重影响着我国人民的健康水平，是目前一个重大社会医疗和健康问题。
针对心脑血管疾病发生的病因，研究者提出了预防和治疗结合的方案，如药物治疗、控制饮食、改善生活方式等方法。药物疗法虽然见效快，但副作用大，容易复发，会对人的身体造成进一步伤害；而食疗法或改善生活方式的效果也不明显且周期较长。国内外目前虽然有很多治疗心脑血管疾病的药物和保健品，但其有效性和安全性不确定，还没有一种特效、安全、天然的用于调节心脑血管健康和减少心脑血管疾病风险的功能性营养食品。
发明内容
本发明的目的在于提供一种调节心脑血管健康和减少心脑血管疾病风险的功能性营养食品。该功能性营养食品配方设计合理巧妙，各组分间相互协同，最大极致的发挥对心脑血管疾病的预防和治疗作用，且该产品安全、有效率高、无毒副作用，是一种预防和治疗心脑血管疾病的最佳的功能性营养食品。
本发明采用以下技术方案：
一种改善心脑血管健康状况的功能性营养食品，它包含以下重量份的有效活性成分原料：纳豆冻干粉20份，红景天提取物15份，水蛭素5份，地龙3份。
它还包含以下重量份的有效活性成分原料：叶酸2份，丹参3份，刺五加5份，银杏5份 ，神经肽2份，红曲5份，藏红花8份。
它包含占药材总重量的10％～20％重量份的辅料，所述的辅料可以是谷类淀粉、或薯类淀粉，或糊精。
所述各原料采用常规制法制成片剂、胶囊剂、口服液或饮料。
本发明的配方依据如下：
纳豆冻干粉是固体发酵的纳豆，经过零下40摄氏度冻结后，经真空抽湿升华干燥、粉碎，成为纳豆冻干粉。纳豆冻干粉可以溶化血栓、修复受损的血液细胞、血管细胞，有效改善冠心病、高血压、动脉硬化、中风、静脉曲张。对于心血管的保健效果十分显著。
红景天提取物为棕色或棕红色粉末，气香甜，味苦涩，微溶于水或乙醇。红景天提取物可缓和压力所致的心血管损伤和紊乱，防止在激动状态下因周围环境压力继发的心脏收缩力下降，起到保护心肌的作用。
水蛭素能高效抗凝血、抗血栓形成，以及阻止凝血酶催化的凝血因子活化和血小板反应等进一步血瘀现象。此外，它还能抑制凝血酶诱导的成纤维细胞的增殖和凝血酶对内皮细胞的刺激。与肝素相比，它不仅用量少，不会引起出血，也不依赖于内源性辅助因子;而肝素则有引起出血的危险，在弥漫性血管内凝血的发病过程中抗凝血酶III往往减少，这将限制肝素的疗效，采用水蛭会有较好的效果。
地龙含有蚓激酶，是由红赤蚯蚓体内提取的一种多酶复合体，具有水解蛋白的功效，用以治疗缺血性脑血管病。
叶酸是制造红血球不可缺少的物质。对心脑血管病人来，造血功能健全有利于心脑血管健康。
丹参加强心肌收缩力、改善心脏功能，不增加心肌耗氧量。
刺五加可补中、益精，强意志，调养心脾，对于心气虚乏所致的心脏病有良效。
银杏含有抗血小板活化因子，可以防止血液的凝集，改善血液循环，防止血栓的形成，含有黄酮能扩张血管，消除自由基，防止动脉硬化，防止心肌梗塞。
神经肽能增强血管收缩，还能导致血管再狭窄。NPY对体外培养的原代血管平滑肌细胞具有明显的增殖作用。
红曲中有效成份是HMG-CoA还原酶的竞争性抑制剂，从而就阻断了合成胆固醇的通路，起到治疗与预防心脑血管疾病的作用。
藏红花对呼吸有兴奋作用，在常压缺氧的条件下，可增大丙酮酸的生成量，提高心肌细胞内乳酸脱氢酶活性，从而可增强细胞内的氧代谢功能，提高心脏的耐缺氧能力，在一定程度上减弱剧烈运动对心肌细胞的损伤，对心脏有一定保护作用。
本发明配方中各成分虽然都有不同程度的降低心脑血管疾病发生概率的作用，但每种组分侧重点和作用机制不同，配合使用后各组分起到协同增效的作用，原料利用率高，对心脑血管疾病的预防及治疗效果显著。本配方所用原料均为市售常规购买原料，安全无毒副作用，本配方制剂的毒理试验也表明是安全的。
本发明的有益效果是：本发明保健品配方设计合理安全，各组分间相互协同作用，可以有效预防心脑血管疾病的发生，改善血脑血管功能，且该产品安全、有效率高、无毒副作用，是一种优质的预防和治疗心脑血管疾病的功能性营养食品。
具体实施方式
下面结合具体实施例对本发明的内容做进一步的详细说明。
实施例1
称取纳豆冻干粉2公斤，红景天提取物1.5公斤，水蛭素0.5公斤，地龙0.3公斤，分别洗净，晾干，加水煎煮 3次，第1次加水量是35公斤，煎煮3小时，沁出煎煮液；第2 次加水量是25公斤，煎煮3小时，沁出煎煮液；第3次加水量是25公斤，煎煮1小时，沁出煎煮液；合并3次的煎煮液，滤过， 浓缩至25℃下相对密度为1.20～1.30的浸膏；之后加入1.1公斤的糊精，混合均匀，干燥、粉碎，装入胶囊制成保健品，每粒装入0.3～0.5g。
上述原料都是从西安森弗生物科技有限公司采购的。
实施例2
称取纳豆冻干粉2公斤，红景天提取物1.5公斤，水蛭素0.5公斤，地龙0.3公斤，叶酸0.2公斤，丹参0.3公斤，刺五加0.5公斤，银杏0.5公斤，神经肽0.2公斤，红曲0.5公斤，藏红花0.8公斤。分别洗净，晾干，加水煎煮 3次，第1次加水量是60公斤，煎煮3小时，沁出煎煮液；第2 次加水量是45公斤，煎煮3小时，沁出煎煮液；第3次加水量是45公斤，煎煮1小时，沁出煎煮液；合并3次的煎煮液，滤过， 浓缩至25℃下相对密度为1.20～1.30的浸膏；之后加入1公斤的糊精，混合均匀，干燥、粉碎，压制成片剂。
实施例3
牟某某，男，74岁，家住辽宁阜新，2008年检查得脑梗，脑梗留下的后遗症，吃饭留米饭粒，流口水，服用本发明功能性营养食品后不流口水，吃饭能自理。
实施例4
徐某某，女，63岁，家住辽宁丹东，检查出腔隙性脑梗赛，口水流不止，住院吊水15天未见好准，后来服用本发明功能性营养食品，不流口水，记忆力恢复。
实施例5
马某某，女，家住上海杨浦区，脑梗赛22天，瞳孔放大，后来苏醒，不能吃不能喝不能动，后来服用本发明功能性营养食品，行动自如，身体恢复很好。
实施例6
金某某，男，79岁，家住上海，大脑严重缺氧，服用本发明功能性营养食品，记忆力明显恢复，不再嗜睡。
Claims (4)
1.一种改善心脑血管健康状况的功能性营养食品，其特征在于，它包含以下重量份的有效活性成分原料：纳豆冻干粉20份，红景天提取物15份，水蛭素5份，地龙3份。
2.根据权利要求1的功能性营养食品，其特征在于，它还包含以下重量份的有效活性成分原料：叶酸2份，丹参3份，刺五加5份，银杏5份 ，神经肽2份，红曲5份，藏红花8份。
3.根据权利要求1或2所述的功能性营养食品，其特征在于，它包含占药材总重量的10％～20％重量份的辅料，所述的辅料可以是谷类淀粉、或薯类淀粉，或糊精。
4.根据权利要求3所述的功能性营养食品，其特征在于，所述各原料采用常规制法制成片剂、胶囊剂、口服液或饮料。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910733483.9A CN110368487A (zh) | 2019-08-09 | 2019-08-09 | 一种改善心脑血管健康状况的功能性营养食品 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910733483.9A CN110368487A (zh) | 2019-08-09 | 2019-08-09 | 一种改善心脑血管健康状况的功能性营养食品 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110368487A true CN110368487A (zh) | 2019-10-25 |
Family
ID=68258738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910733483.9A Pending CN110368487A (zh) | 2019-08-09 | 2019-08-09 | 一种改善心脑血管健康状况的功能性营养食品 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110368487A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113368223A (zh) * | 2020-02-25 | 2021-09-10 | 张旺凡 | 一种用于心脑血管病防治的中药复方分散片及制备方法 |
| CN113559208A (zh) * | 2021-08-27 | 2021-10-29 | 浙江天真健康科技有限公司 | 一种保护心脑血管的中药组合物及其制备方法 |
| CN114246917A (zh) * | 2022-02-28 | 2022-03-29 | 深圳德荫堂生物科技有限公司 | 一种缓解心脑血管疾病生物药剂及生产方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103393114A (zh) * | 2013-08-06 | 2013-11-20 | 西藏月王生物技术有限公司 | 以青稞红曲为主降脂养心增强免疫力的制剂及制备方法 |
| CN105796625A (zh) * | 2014-12-31 | 2016-07-27 | 北京北大维信生物科技有限公司 | 含红曲红花的药物组合物及其制剂 |
| CN108125091A (zh) * | 2018-01-22 | 2018-06-08 | 斯汏克（北京）生物科技有限公司 | 一种改善心脑血管中草药植物复合酵素饮品的制备方法 |
| CN109200279A (zh) * | 2018-10-26 | 2019-01-15 | 路领群 | 一种溶解血栓、抗血凝的药物组合物 |
| CN109393494A (zh) * | 2018-10-25 | 2019-03-01 | 丽睿客信息科技（北京）有限公司 | 一种中老年用保健食品组合物及其应用 |
-
2019
- 2019-08-09 CN CN201910733483.9A patent/CN110368487A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103393114A (zh) * | 2013-08-06 | 2013-11-20 | 西藏月王生物技术有限公司 | 以青稞红曲为主降脂养心增强免疫力的制剂及制备方法 |
| CN105796625A (zh) * | 2014-12-31 | 2016-07-27 | 北京北大维信生物科技有限公司 | 含红曲红花的药物组合物及其制剂 |
| CN108125091A (zh) * | 2018-01-22 | 2018-06-08 | 斯汏克（北京）生物科技有限公司 | 一种改善心脑血管中草药植物复合酵素饮品的制备方法 |
| CN109393494A (zh) * | 2018-10-25 | 2019-03-01 | 丽睿客信息科技（北京）有限公司 | 一种中老年用保健食品组合物及其应用 |
| CN109200279A (zh) * | 2018-10-26 | 2019-01-15 | 路领群 | 一种溶解血栓、抗血凝的药物组合物 |
Non-Patent Citations (1)
| Title |
|---|
| 傅欣彤等: "HPLC法测定复方红景天胶囊中红景天苷和紫丁香苷的含量", 《药物分析杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113368223A (zh) * | 2020-02-25 | 2021-09-10 | 张旺凡 | 一种用于心脑血管病防治的中药复方分散片及制备方法 |
| CN113559208A (zh) * | 2021-08-27 | 2021-10-29 | 浙江天真健康科技有限公司 | 一种保护心脑血管的中药组合物及其制备方法 |
| CN114246917A (zh) * | 2022-02-28 | 2022-03-29 | 深圳德荫堂生物科技有限公司 | 一种缓解心脑血管疾病生物药剂及生产方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110368487A (zh) | 一种改善心脑血管健康状况的功能性营养食品 | |
| EP3006034B1 (en) | Multi-functional composition and preparation method and application thereof | |
| KR100966613B1 (ko) | 혈당상승억제 효능을 나타내는 아르기닌 유도체 또는 이의 염을 포함하는 조성물의 제조방법 | |
| CN112999261B (zh) | 一种舒缓动脉硬化的纳豆发酵组合物及其制备方法和应用 | |
| CN108653539A (zh) | 一种降低尿酸药食同源压片及其制备方法 | |
| CN108095113A (zh) | 一种具有减脂降糖作用的组合物、制剂及其应用 | |
| CN101473943B (zh) | 一种改善记忆功能的保健食品及其制备方法 | |
| CN108671002A (zh) | 一种含雪莲培养物提取物的组合物及其应用 | |
| CN104758404B (zh) | 一种复方三蛇粉组合物及其制备方法 | |
| CN101961367B (zh) | 一种预防酒精性肝损伤的中药组合物 | |
| CN109123351A (zh) | 一种具有高血糖人群代餐调节功能的特医食品及制备方法 | |
| KR102189416B1 (ko) | 금불초 복합추출물을 유효성분으로 함유하는 비만 예방 및 체지방 감소용 조성물 | |
| CN109395028A (zh) | 一种预防、治疗三高症的葛景甲参酒配方及制备方法 | |
| KR20150015305A (ko) | 주박 추출물을 유효성분으로 함유하는 비만의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품 | |
| KR20180079920A (ko) | 토사자 추출물을 유효성분으로 함유하는 간섬유화 또는 간경화 예방, 개선 또는 치료용 조성물 | |
| EP3616697A1 (en) | Use of a pharmaceutical carrier in the preparation of an anti-diabetic pharmaceutical composition | |
| CN103766885A (zh) | 缓解体力疲劳的保健食品 | |
| CN105076614A (zh) | 减肥保健茶 | |
| CN108379455B (zh) | 一种降尿酸组合物 | |
| KR20140143271A (ko) | 홍삼 복합물을 유효 성분으로 함유하는 죽상경화증 예방, 개선 또는 치료를 위한 조성물 | |
| CN107411062A (zh) | 枸杞瘦身酵素 | |
| CN103054906A (zh) | 用于解酒的蜂胶乙醇提取物、制备方法及在生产***片中的应用 | |
| CN103251743B (zh) | 一种提高免疫力、改善心脑血管功能、延缓衰老的制剂 | |
| CN106109951A (zh) | 防治高血糖、高血脂、高血压的药物及其制备方法 | |
| CN102657333B (zh) | 降压护心复合营养剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20191025 |